<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135680</url>
  </required_header>
  <id_info>
    <org_study_id>HPN-100-010</org_study_id>
    <nct_id>NCT01135680</nct_id>
  </id_info>
  <brief_title>Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100</brief_title>
  <official_title>Double-Blind Randomized Placebo-Control Trial to Evaluate Electrocardiogram Effects of HPN-100 as Defined by Clinical and Supratherapeutic Dose in Healthy Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Pharma Ireland, Ltd., Dublin Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Pharma Ireland, Ltd., Dublin Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arm 1:&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      • To determine the safety and tolerability of multiple ascending, supratherapeutic doses of&#xD;
      HPN-100.&#xD;
&#xD;
      Arm 2:&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      • To assess the effects of steady-state levels of HPN-100 metabolites (4 phenylbutyric acid&#xD;
      [PBA], phenylacetic acid [PAA], and phenylacetylglutamine [PAGN]) on 12-lead&#xD;
      electrocardiogram (ECG) parameters in healthy male and female subjects with the primary&#xD;
      endpoint being the time-matched change from baseline in the QT interval corrected for heart&#xD;
      rate (HR) based on an individual correction method (QTcI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the effects of steady-state levels of HPN-100 metabolites (4-phenylbutryic acid (PBA),&#xD;
      phenylacetic acid (PAA), and phenylacetylglutamine (PAGN) on 12-lead electrocardiogram (ECG)&#xD;
      parameters in health male and female subjects with the primary endpoint being the&#xD;
      time-matched change from baseline in the QT interval corrected for heart rate(HR) based on an&#xD;
      individual correction method (QTcl).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by the rate and severity of adverse events in each treatment group.</measure>
    <time_frame>3-day treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline QTcI as a measure of effects of study-state HPN-100 metabolites: PBA, PAA, and PAGN</measure>
    <time_frame>4 treatment regimens for 3 days with a 4 day minimum washout period between treatments</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlate time-matched ECG waveform changes to steady-state levels of HPN-100 by using QTcB and QTcF formulas to assess ECG morphologic changes.</measure>
    <time_frame>4 treatment regimens for 3 days with a 4 day minimum washout period between treatments</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate time-matched QTcI change from baseline and serum levels of PBA, PAA, and PAGN drawn on Day 1, Day 2, Day 3, and Day 4</measure>
    <time_frame>4 treatment regimens for 3 days with a 4 day minimum washout period between treatments</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender differences in metabolism of HPN-100 as measured by time-matched serum levels of HTN-100, PBA, PAA, and PAGN via samples drawn on Day 1, Day 2, Day 3, and Day 4.</measure>
    <time_frame>4 treatment regimens for 3 days with a 4 day minimum washout period between treatments</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events in each treatment group.</measure>
    <time_frame>4 treatment regimens for 3 days with a 4 day minimum washout period between treatments</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Drug Toxicity</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A: 9 mL HPN-100 or placebo&#xD;
Cohort B: 12 mL HPN-100 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This study requires 4 periods. In each of the periods you will receive one of the dose groups listed below. At the completion of the study you will have participated in all 4 dose groups. The order in which you participate in each dose group will be randomly assigned.&#xD;
Dose Group A: 9 mL placebo via oral syringe 3 times daily for 3 days&#xD;
Dose Group B: single oral dose of 400 mg moxifloxacin on study Day 3&#xD;
Dose Group C: 6 mL HPN-100 and 3 mL placebo via oral syringe 3 times daily for 3 days&#xD;
Dose Group D: 9 mL HPN-100 via oral syringe 3 times daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPN-100</intervention_name>
    <description>single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPN-100 or Placebo</intervention_name>
    <description>single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>single oral 400-mg dose on study Day 3</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPN-100</intervention_name>
    <description>single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPN-100</intervention_name>
    <description>single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be in good health&#xD;
&#xD;
          -  Negative hepatitis panel and negative HIV antibody screens&#xD;
&#xD;
          -  Females must be non-pregnant, non-lactating, and either postmenopausal or agree to to&#xD;
             use adequate contraceptive methods throughout the study&#xD;
&#xD;
          -  Males must either be sterile or willing to use adequate contraceptive methods&#xD;
             throughout the study&#xD;
&#xD;
          -  Willing and able to comply with all trial requirements&#xD;
&#xD;
          -  Able to comprehend and willing to sign an Informed Consent Form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or clinical manifestations of significant allergic, metabolic, hepatic, renal,&#xD;
             endocrine, hematological, pulmonary, cardiovascular, gastrointestinal, urological,&#xD;
             neurological, or psychiatric disorders&#xD;
&#xD;
          -  History of hypersensitivity or allergies to any drug compound&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection&#xD;
&#xD;
          -  History or presence of an abnormal ECG&#xD;
&#xD;
          -  History of alcoholism or drug addiction within 1 year&#xD;
&#xD;
          -  Use of any tobacco-containing or nicotine-containing products within 3 months&#xD;
&#xD;
          -  Participated in any other clinical trial of an investigational drug (or a medical&#xD;
             device) within 30 days&#xD;
&#xD;
          -  Use of any prescription medications/products other than contraceptives within 14 days&#xD;
&#xD;
          -  Use of any over-the-counter, non-prescription preparations (including vitamins,&#xD;
             minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days&#xD;
&#xD;
          -  Test positive for drug(s) of abuse, ethanol, or cotinine&#xD;
&#xD;
          -  Have donated blood or blood components within 30 days&#xD;
&#xD;
          -  Have received blood products within 2 months&#xD;
&#xD;
          -  Have a history of unexplained syncope&#xD;
&#xD;
          -  Have a family history of unexplained sudden death&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Pharmacology, Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>May 31, 2010</study_first_submitted>
  <study_first_submitted_qc>May 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

